Keywords: Bristol-Myers, Medivir, Janssen, Johnson & Johnsonm Hepatitis C, Collaboration expanded, Daclastasvir

Bristol-Myers expands hepatitis C accord with Medivir and Janssen

Article | 18 April 2012

Print This

Swedish infectious disease drug developer Medivir AB (OMX: MVIR) said yesterday that its development partner, Janssen R&D Ireland, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in